Retinoid X receptor agonist combined with platinum-based chemotherapy and taxane

This page covers all Retinoid X receptor agonist combined with platinum-based chemotherapy and taxane drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting RXR (retinoid X receptor); DNA (carboplatin); β-tubulin (paclitaxel).

Targets

RXR (retinoid X receptor); DNA (carboplatin); β-tubulin (paclitaxel)

Phase 3 pipeline (1)

• bexarotene with carboplatin and paclitaxel · Eisai Inc. · Oncology
  This combination uses bexarotene (a retinoid X receptor agonist) to enhance immune response alongside carboplatin and paclitaxel chemotherapy agents that damage cancer cell DNA and disrupt microtubule function.

Patent intelligence

• retinoid x receptor agonist combined with platinum based chemotherapy and taxane patent landscape — aggregated cliff calendar, attackable patents, originator estates